At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 167 enrolled
Drug / intervention
Ferric maltol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease
In Brief
A Phase 3 clinical trial evaluating Ferric maltol and Placebo for Renal Insufficiency, Chronic and Iron-Deficiency Anemia. Completed, enrolled 167 participants across 27 sites.
Detailed Summary
To evaluate the efficacy of oral ferric maltol compared with placebo in the treatment of IDA in subjects with CKD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionJan 2018
Study CompletionOct 2018
TodayJul 2026
First PostedNov 18, 2016
Enrollment StartDec 1, 2016
Primary CompletionJan 18, 2018
Study CompletionOct 10, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.6 years ago
Interventions
Ferric maltoldrug
Placeboother